Hyperkalemia: The Complete USMLE Guide for Step 1, Step 2 CK, and Step 3

Hyperkalemia: The Complete USMLE Guide for Step 1, Step 2 CK, and Step 3

Hyperkalemia is a perfect "connect the dots" topic across the USMLE — the cellular electrophysiology on Step 1, the emergency stabilize-shift-eliminate sequence on Step 2 CK, and the chronic outpatient management of recurrent causes on Step 3. It's also one of the highest-stakes topics in medicine, since severe hyperkalemia can kill a patient in minutes via arrhythmia.

This guide from themedicosmd.com walks through a real exam-style vignette at each level.

Table of Contents

Step 1: Cellular Mechanism & ECG Changes

Step 2 CK: Emergency Management

Step 3: Chronic Outpatient Management

High-Yield Review Table

FAQ

Step 1: Cellular Mechanism & ECG Changes

Vignette: A patient with severe hyperkalemia (potassium 7.2 mEq/L) undergoes ECG monitoring, which shows peaked T waves and a widened QRS complex. Which of the following best explains this ECG change at the cellular level?

Decreased resting membrane potential (less negative), impairing fast sodium channel function and slowing conduction

Increased resting membrane potential (more negative), hyperpolarizing cardiac myocytes

Direct blockade of calcium channels by excess potassium

Increased sodium-potassium ATPase activity

Prolongation of the sodium channel inactivation state

Answer: Decreased resting membrane potential (less negative), impairing fast sodium channel function and slowing conduction.

Explanation: The resting membrane potential of a cardiac myocyte is largely determined by the potassium gradient across the cell membrane. As extracellular potassium rises, the gradient driving potassium out of the cell decreases, so the resting membrane potential becomes less negative (depolarized) — closer to threshold. Paradoxically, this partial depolarization causes many fast voltage-gated sodium channels to become inactivated (they need to reset from a sufficiently negative resting potential to be available again), which slows cardiac conduction velocity. This is why the ECG shows peaked T waves early (faster repolarization from certain potassium channel effects) and then progressively widened QRS complexes as conduction slows further — a warning sign of impending, potentially fatal arrhythmia (sine wave pattern, ventricular fibrillation, asystole).

Step 1 pearl: Know the ECG progression in order: peaked T waves → PR prolongation/flattened P waves → widened QRS → sine wave pattern → ventricular fibrillation/asystole. The exam frequently shows an ECG and asks you to identify the severity based on which stage you see.

Step 2 CK: Emergency Management

Vignette: A 58-year-old man with chronic kidney disease presents with muscle weakness. Potassium is 7.4 mEq/L, and ECG shows peaked T waves and a widened QRS. Which of the following should be administered first?

IV insulin with dextrose

IV calcium gluconate

Sodium polystyrene sulfonate

Hemodialysis

Oral potassium binder

Answer: IV calcium gluconate.

Explanation: With ECG changes present (peaked T waves plus a widened QRS — evidence of cardiac membrane instability), the very first priority is to stabilize the cardiac cell membrane, and IV calcium gluconate does this within minutes by raising the threshold potential, counteracting the sodium channel effects of hyperkalemia — without actually lowering the serum potassium level at all. Once the membrane is stabilized, the next steps shift potassium intracellularly (IV insulin with concurrent dextrose to prevent hypoglycemia, plus beta-2 agonists like nebulized albuterol) to rapidly but temporarily lower serum potassium, and finally eliminate potassium from the body (potassium binders, loop diuretics if the patient makes urine, or hemodialysis for refractory cases or severe renal failure).

Step 2 CK pearl: Memorize the sequence as "stabilize, shift, eliminate" — calcium gluconate stabilizes the membrane (no ECG changes present? skip straight to shifting), insulin/glucose and albuterol shift potassium into cells temporarily, and binders/diuretics/dialysis actually remove potassium from the body. Confusing the order (e.g., giving insulin before calcium in an unstable patient) is a classic wrong-answer trap.

Step 3: Chronic Outpatient Management

Vignette: A 58-year-old man with chronic kidney disease and heart failure is seen in clinic. He was recently hospitalized for hyperkalemia. He is on an ACE inhibitor and spironolactone for his heart failure, both of which are important for his long-term cardiovascular prognosis. Which of the following is the most appropriate next step in his outpatient management?

Immediately and permanently discontinue both the ACE inhibitor and spironolactone

Review and optimize his diet, consider dose adjustment, and evaluate for a potassium binder to allow continuation of his cardioprotective medications when possible

No changes needed since the hyperkalemia episode has resolved

Switch him to a different ACE inhibitor at the same dose, since the class doesn't matter

Start a thiazide diuretic to correct his potassium instead

Answer: Review and optimize his diet, consider dose adjustment, and evaluate for a potassium binder to allow continuation of his cardioprotective medications when possible.

Explanation: This is a nuanced Step 3 systems-based practice question that many students get wrong by defaulting to "just stop the offending drugs." ACE inhibitors and mineralocorticoid receptor antagonists like spironolactone are both RAAS inhibitors that predispose to hyperkalemia — but they're also proven to reduce mortality in heart failure. The modern, guideline-supported approach is to try to preserve these cardioprotective medications where possible, using dietary potassium restriction, careful dose adjustment, monitoring, and newer potassium-binding agents (like patiromer or sodium zirconium cyclosilicate) to manage the potassium — rather than reflexively discontinuing drugs that are keeping him alive longer from a cardiovascular standpoint. Outright discontinuation is sometimes necessary for severe or recurrent hyperkalemia, but it's not the automatic first move.

Step 3 pearl: When a Step 3 vignette pits a drug's side effect against its major proven benefit (here, hyperkalemia risk vs. mortality benefit in heart failure), the correct answer is usually to manage the side effect proactively rather than simply removing the beneficial drug — this reflects real guideline-based practice, not just theoretical pharmacology.

High-Yield Review Table

Feature Key Point

Cellular mechanism Decreased K+ gradient → less negative resting membrane potential → sodium channel inactivation → slowed conduction

ECG progression Peaked T waves → PR prolongation/flat P waves → widened QRS → sine wave → V-fib/asystole

First step if ECG changes present IV calcium gluconate (stabilizes membrane, doesn't lower K+)

Shift potassium intracellularly IV insulin + dextrose, nebulized albuterol

Eliminate potassium Potassium binders, loop diuretics, hemodialysis (severe/refractory)

Common outpatient causes CKD, ACE-I/ARB/spironolactone, NSAIDs, potassium-sparing diuretics

Chronic management principle Try to preserve cardioprotective RAAS-inhibiting drugs when possible using diet, dose adjustment, and binders

Frequently Asked Questions

What is the first step in treating hyperkalemia with ECG changes?

IV calcium gluconate, which stabilizes the cardiac cell membrane within minutes without actually lowering the serum potassium level.

What is the correct order of hyperkalemia treatment?

Stabilize the cardiac membrane (calcium gluconate) if ECG changes are present, then shift potassium intracellularly (insulin with dextrose, albuterol), then eliminate potassium from the body (binders, diuretics, or dialysis).

Should ACE inhibitors always be stopped if a patient develops hyperkalemia?

Not automatically. Given their proven mortality benefit in heart failure and CKD, the modern approach favors preserving these medications where possible through dietary changes, dose adjustment, and potassium binders, reserving discontinuation for severe or recurrent cases.

Is hyperkalemia tested across all three USMLE steps?

Yes. Step 1 tests the cellular mechanism and ECG changes, Step 2 CK tests emergency management sequencing, and Step 3 tests chronic outpatient management balancing side effects against a medication's benefits.

Want More USMLE Vignettes Like This?

Part of our ongoing USMLE Step 1, Step 2 CK, and Step 3 vignette series from themedicosmd.com.

Visit themedicosmd.com to book a tutoring session or browse more high-yield breakdowns.